36. Epidermolysis bullosa Clinical trials / Disease details
Clinical trials : 163 / Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125
Showing 1 to 10 of 163 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04173650 (ClinicalTrials.gov) | October 2023 | 18/11/2019 | MSC EVs in Dystrophic Epidermolysis Bullosa | A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatmen ... | Dystrophic Epidermolysis Bullosa | Drug: AGLE 102 | Aegle Therapeutics | NULL | Not yet recruiting | 6 Years | N/A | All | 10 | Phase 1/Phase 2 | NULL |
| 2 | NCT05725018 (ClinicalTrials.gov) | March 24, 2023 | 23/1/2023 | EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bul ... | A Phase 3b Study for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in New and Previously EB-101 Treated Patients A Phase 3b Study for the Treatment of Recessive Dystrophic Epidermolysis Bullosa(RDEB) in New and Pr ... | Epidermolysis Bullosa;Recessive Dystrophic Epidermolysis Bullosa;RDEB | Biological: EB-101 Surgical application of RDEB wounds | Abeona Therapeutics, Inc | NULL | Not yet recruiting | 6 Years | N/A | All | 12 | Phase 3 | United States |
| 3 | NCT05464381 (ClinicalTrials.gov) | February 1, 2023 | 5/7/2022 | Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over) Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa(Ph ... | A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB) A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Tria ... | Epidermolysis Bullosa | Drug: allo-APZ2-OTS;Drug: Placebo | RHEACELL GmbH & Co. KG | NULL | Recruiting | N/A | N/A | All | 74 | Phase 3 | Austria |
| 4 | NCT05651607 (ClinicalTrials.gov) | January 2023 | 7/12/2022 | Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis ... | Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis ... | Hereditary Epidermolysis Bullosa | Drug: Cannabidiol | Assistance Publique - Hôpitaux de Paris | HELEBOR;Fondation Apicil;Lions Club International Foundation | Not yet recruiting | 2 Years | 17 Years | All | 10 | Phase 2 | France |
| 5 | NCT05157958 (ClinicalTrials.gov) | November 1, 2022 | 2/12/2021 | Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bu ... | Double Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET Versus Vehicle Control in Dystrophic Epidermolysis Bullosa (DEB) Patients Double Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET ... | Dystrophic Epidermolysis Bullosa | Biological: ALLO-ASC-SHEET;Other: Vehicle Control | Anterogen Co., Ltd. | NULL | Not yet recruiting | 4 Years | 60 Years | All | 6 | Phase 2 | NULL |
| 6 | NCT05529134 (ClinicalTrials.gov) | October 1, 2022 | 1/9/2022 | Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis BullosaDue to Mutat ... | A Double-blind, Randomized, Intra-patient Placebo- Controlled, Multiple Dose Study of PTW-002 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy, and Systemic Exposure in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa (DDEB / RDEB) Due to Mutation(s) in Exon 73 of the COL7A1 Gene A Double-blind, Randomized, Intra-patient Placebo- Controlled, Multiple Dose Study of PTW-002 Evalua ... | Dystrophic Epidermolysis Bullosa | Drug: PTW-002 10 mg/g gel;Drug: Placebo | Phoenicis Therapeutics | NULL | Not yet recruiting | 4 Years | N/A | All | 8 | Phase 1/Phase 2 | United States |
| 7 | EUCTR2021-000214-42-ES (EUCTR) | 08/03/2022 | 17/12/2021 | INM-755 cream for patients with EB. | A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (cannabinol) Cream in Patients with Epidermolysis Bullosa. A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (cannabino ... | Epidermolysis bullosa MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Epidermolysis bullosa MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysi ... | Product Name: Cannabinol (CBN) Product Code: INM-755 INN or Proposed INN: CANNABINOL | InMed Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | France;Serbia;Greece;Spain;Austria;Israel;Germany;Italy | ||
| 8 | NCT04908215 (ClinicalTrials.gov) | December 28, 2021 | 26/5/2021 | INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa | A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabino ... | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa, Junctional;Epidermolysis Bullosa Dystrophica;Kindler Syndrome Epidermolysis Bullosa Simplex;Epidermolysis Bullosa, Junctional;Epidermolysis Bullosa Dystrophica;Ki ... | Drug: INM-755 (cannabinol) cream;Drug: Vehicle Cream | InMed Pharmaceuticals Inc. | NULL | Recruiting | 12 Years | N/A | All | 20 | Phase 2 | Austria;France;Germany;Greece;Israel |
| 9 | NCT05143190 (ClinicalTrials.gov) | December 2, 2021 | 9/11/2021 | Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01) Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa(RDEB) Patients ... | A Phase 2b Open-Label Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01 in Study PTR-01-002 A Phase 2b Open-Label Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa(RDEB) Patients P ... | Recessive Dystrophic Epidermolysis Bullosa | Drug: PTR-01 | Phoenix Tissue Repair, Inc. | Phoenix Tissue Repair, a BridgeBio company | Completed | 12 Years | N/A | All | 2 | Phase 2 | United States |
| 10 | EUCTR2018-000261-36-IT (EUCTR) | 07/09/2021 | 07/10/2020 | Gene Therapy for patient with Junctional Epidermolysis Bullosa | MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR RESTORATION OF EPIDERMIS IN PATIENTS WITH JUNCTIONAL EPIDERMOLYSIS BULLOSA (HOLOGENE 5) - Hologene 5 MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF ... | Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility ofskin and mucosal membranes, impairing the patient's quality of life. Generalized JEB is a chronic, life-threatening condition caused bymutations in genes– encoding different chains of laminin 332. All of these mutations hamper hemidesmosome formation, causing blisters. The most frequent, and perhaps most severe, JEB is due to mutations in LAMB3. MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Inherited Epidermolysis Bullosa(EB) is a group of rare, devastating genetic disorders characterized ... | Product Name: Hologene 5 Product Code: [Hologene 5 DS] Other descriptive name: Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA. Product Name: Hologene 5 Product Code: [Hologene 5DS] Other descriptive name: Ex-vivo expanded autolog ... | HOLOSTEM TERAPIE AVANZATE S.R.L. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 6 | Phase 2;Phase 3 | France;Germany;Italy |